Fifteen Years of Cell-Penetrating Guanidinium-Rich Molecular Transporters: Basic Science, Research Tools, and Clinical Applications

All living systems require biochemical barriers. As a consequence, all drugs, imaging agents, and probes have targets that are either on, in, or inside of these barriers. Fifteen years ago, we initiated research directed at more fully understanding these barriers and at developing tools and strategies for breaching them that could be of use in basic research, imaging, diagnostics, and medicine. At the outset of this research and now to a lesser extent, the rules for drug design biased the selection of drug candidates mainly to those with an intermediate and narrow log P. At the same time, it was becoming increasingly apparent that Nature had long ago developed clever strategies to circumvent these rules. In 1988, for example, independent reports documented the otherwise uncommon passage of a protein (HIV-Tat) across a membrane. A subsequent study implicated a highly basic domain in this protein (Tat(49-57)) in its cellular entry. This conspicuously contradictory behavior of a polar, highly charged peptide passing through a nonpolar membrane set the stage for leaning how Nature had gotten around the current rules of transport. As elaborated in our studies and discussed in this Account, the key strategy used in Nature rests in part on the ability of a molecule to change its properties as a function of microenvironment; such molecules need to be polarity chameleons, polar in a polar milieu and relatively nonpolar in a nonpolar environment. Because this research originated in part with the protein Tat and its basic peptide domain, Tat(49-57), the field focused heavily on peptides, even limiting its nomenclature to names such as cell-penetrating peptides, cell-permeating peptides, protein transduction domains, and membrane translocating peptides. Starting in 1997, through a systematic reverse engineering approach, we established that the ability of Tat(49-57) to enter cells is not a function of its peptide backbone, but rather a function of the number and spatial array of its guanidinium groups. These function-oriented studies enabled us and others to design more effective peptidic agents and to think beyond the confines of peptidic systems to new and even more effective nonpeptidic agents. Because the function of passage across a cell membrane is not limited to or even best achieved with the peptide backbone, we referred to these agents by their shared function, cell-penetrating molecular transporters. The scope of this molecular approach to breaching biochemical barriers has expanded remarkably in the past 15 years: enabling or enhancing the delivery of a wide range of cargos into cells and across other biochemical barriers, creating new tools for research, imaging, and diagnostics, and introducing new therapies into clinical trials.